Anticoagulation prescription in atrial fibrillation

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 10, 2011, Pages 1473-1479

  Bertomeu González, Vicente ^a   Cordero, Alberto ^a   Mazón, Pilar ^b   Moreno Arribas, José ^a   Fácila, Lorenzo ^c   Nuñez, Julio ^d   Rodríguez Mañero, Moisés ^e   Cosín Sales, Juan ^f   González Juanatey, Jose Ramón ^b   Quiles, Juan ^a   Bertomeu Martínez, Vicente ^a  

^a HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL PROVINCIAL DE CASTELLÓN   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

^f HOSPITAL ARNAU DE VILANOVA   (Spain)

Author keywords

anticoagulation; antiplatelet treatment; atrial fibrillation

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIAC PATIENT; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PRESCRIPTION; PROGNOSIS; RISK FACTOR; SCORING SYSTEM; SMOKING; STROKE; VALVULAR HEART DISEASE;

AGED; AGED, 80 AND OVER; AMBULATORY CARE FACILITIES; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HEMORRHAGE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; THROMBOSIS;

EID: 79958737115     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.584063     Document Type: Article

References (26)

1. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001;12(5):516-21 (Pubitemid 32999861)
2. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31(19):2369-429
3. McCormick D, Gurwitz JH, Goldberg RJ, Ansell J. Long-term anticoagulation therapy for atrial fibrillation in elderly patients: efficacy, risk, and current patterns of use. J Thromb Thrombolysis 1999;7(2):157-63 (Pubitemid 29224997)
4. Carlsson J, Miketic S, Dees G, et al. Stroke prevention practices in patients with atrial fibrillation and pacemaker therapy: evidence for under-use of anticoagulation. Europace 2000;2(2):115-18
5. Cohen N, Almoznino-Sarafian D, Alon I, et al. Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Stroke 2000;31(6):1217-22 (Pubitemid 30351236)
6. McBride D, Bruggenjurgen B, Roll S, Willich SN. Anticoagulation treatment for the reduction of stroke in atrial fibrillation: a cohort study to examine the gap between guidelines and routine medical practice. J Thromb Thrombolysis 2007;24(1):65-72 (Pubitemid 46838499)
7. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137(2):263-72
8. Mancia G, De Backer G, Dominiczak A, et al. The task force for the management of arterial hypertension of the European Society of H, The task force for the management of arterial hypertension of the European Society of C. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28(12):1462-536
9. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285(22):2864-70 (Pubitemid 32537350)
10. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Chest 2010;138(5):1093-100
11. Bertomeu V, Morillas P, Gonzalez-Juanatey JR, et al. Antithrombotic treatment in hypertensive patients with chronic atrial fibrillation. CARDIOTENS 99 study. Med Clin 2002;118(9):327-31
12. Morillas P, Pallares V, Llisterri JL, et al. Prevalence of atrial fibrillation and use of antithrombotics in hypertensive patients aged > or=65 years. The FAPRES trial. Rev Esp Cardiol 2010;63(8):943-50
13. Schwammenthal Y, Bornstein NM, Goldbourt U, et al. Anticoagulation remains underused in prevention of stroke associated with atrial fibrillation: insights from two consecutive national surveys. Int J Cardiol 17 Sep 2010. [Epub ahead of print]
14. Kowey PR, Reiffel JA, Myerburg R, et al. Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS Registry). Am J Cardiol 2010;105(8):1130-4
15. Poli D, Lip GY, Antonucci E, et al. Stroke risk stratification in a Real-World elderly anticoagulated atrial fibrillation population. J Cardiovasc Electrophysiol 2011;22(1):25-30
16. Pisters R, van Oostenbrugge RJ, Knottnerus IL, et al. The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines. Europace 2010;12(6):779-84
17. McCormick D, Gurwitz JH, Goldberg RJ, et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med 2001;161(20):2458-63 (Pubitemid 33043119)
18. Waldo AL, Becker RC, Tapson VF, Colgan KJ. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol 2005;46(9):1729-36 (Pubitemid 41531631)
19. Agarwal S, Bennett D, Smith DJ. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting. Am J Cardiovasc Drugs 2010;10(1):37-48
20. Fauchier L, Lip GY. Guidelines for antithrombotic therapy in atrial fibrillation: understanding the reasons for non-adherence and moving forwards with simplifying risk stratification for stroke and bleeding. Europace 2010;12(6):761-3
21. Gorin L, Fauchier L, Nonin E, et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1. Thromb Haemost 2010;103(4):833-40
22. Cohen BJ, Pauker SG. How do physicians weigh iatrogenic complications? J Gen Intern Med 1994;9(1):20-3 (Pubitemid 24034267)
23. Inoue H, Nozawa T, Hirai T, et al. Accumulation of risk factors increases risk of thromboembolic events in patients with nonvalvular atrial fibrillation. Circ J 2006;70(6):651-6 (Pubitemid 43803693)
24. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347(23):1825-33 (Pubitemid 35417773)
25. Atrial Fibrillation Investigators: Atrial Fibrillation, Aspirin, Anticoagulation Study; Boston Area Anticoagulation Trial for Atrial Fibrillation Study; Canadian Atrial Fibrillation Anticoagulation Study; Stroke Prevention in Atrial Fibrillation Study; Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Study. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154(13):1449-57
26. Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000;35(1):183-7 (Pubitemid 30061278)